Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-guided tricyclic antidepressant dosing in severe major depressive disorder
NL-OMON49004Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of imipramine, nortriptyline and clomipramine in major depressive disorder (MDD) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Time to therapeutic TCA plasma concentration. Started May 2018; status: completed.
02
Drugs
imipraminenortriptylineclomipramine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON49004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49004.